In Monday’s Blitz Daily with Lance Ippolito, we take a look at pharmaceutical giant Pfizer after new lockdown headlines spread through the media.
We may be done with the omicron variant but by the looks of news coming out of China, it’s not quite done with us.
The People’s Republic is experiencing its largest outbreak since the early days of the pandemic. More than 10,000 cases of omicron have been reported since the start of March. The spike in cases pushed officials to lock down two major cities, including Shenzhen, a big tech hub.
The news sparked a rally in several of the coronavirus plays including top vaccine name Pfizer, which saw shares up more than 4% Monday!
Of course, if you’re sick of trading pharma names, I have three more top trades waiting inside…
Disclaimer: The material in this document is for informational purposes based on our proprietary research. It is not an offering, specific recommendation, or a solicitation of an offer to buy or sell any securities mentioned or discussed herein.
Any performance results discussed herein represent past performance, are not a guarantee of future performance, and are not indicative of any specific investment.
Due to the timing of information presented, any investment performance reflected within this document may be adjusted after the publication and distribution of this material. There can be no assurance that the future performance of any specific investment, investment strategy, or product made reference to directly or indirectly in this communication will be profitable, be equal to any corresponding indicated historical performance levels or be suitable for your portfolio. Any investment results set forth in this document are not net of expenses and execution costs, nor do they account for other relevant trading or investment fees. Please visit wealthpress.com/terms for our full Terms and Conditions.
0 Response to "Bullish Options Traders Turn to Pfizer to Cure Bear Market Blues"
Post a Comment